8-K: Relmada Therapeutics Announces Fourth Quarter and Full Year 2024 Results, Provides Business Update

Relmada Therapeutics reports its Q4 and full year 2024 financial results, highlighting progress with NDV-01 and sepranolone programs and a cash balance of $44.8 million.

Summary

• Relmada Therapeutics announced its fourth quarter and full year 2024 financial results.
• The company is advancing NDV-01 for bladder cancer, with Phase 2 data expected at the AUA meeting in April 2025.
• They are also progressing sepranolone towards a Phase 2b study for Tourette syndrome and exploring its use in other compulsion-related disorders.
• Relmada reported a cash balance of $44.8 million as of December 31, 2024.
• The company is re-evaluating further development of P11 due to prioritization efforts and increased competition.
• The net loss for the year ended December 31, 2024, was $80 million, or $2.65 per share, compared to a net loss of $98.8 million, or $3.28 per share, for the year ended December 31, 2023.

Sentiment

Score: 7

Explanation: The sentiment is cautiously optimistic. While the company reported a net loss, it has a solid cash position, is advancing promising clinical programs, and has reduced operating expenses. The focus on strategic acquisitions and underserved markets is also a positive sign.

Positives

• Relmada has a solid cash position of $44.8 million, which is expected to fund operations into H1 2026.
• The company has acquired two Phase 2 programs, NDV-01 and sepranolone, which are seen as value-creation opportunities.
• The company is focusing on programs with near-term value drivers that address underserved markets.
• Research and development expenses decreased by $8.6 million for the year ended December 31, 2024, compared to the previous year.
• General and administrative expenses decreased by approximately $11.2 million for the year ended December 31, 2024, compared to the previous year.
• The net loss decreased from $98.8 million in 2023 to $80 million in 2024.

Negatives

• The company had a net loss of $80 million for the year ended December 31, 2024.
• Cash, cash equivalents, and short-term investments decreased from $96.3 million at December 31, 2023, to approximately $44.9 million at December 31, 2024.
• The company is re-evaluating further development of P11, indicating a potential setback for that program.

Risks

• The success of NDV-01 and sepranolone depends on positive Phase 2 data and successful interactions with the FDA.
• Failure to secure adequate drug supply for sepranolone or NDV-01 could hinder development.
• Clinical trials may not deliver statistically significant evidence of efficacy and/or safety.
• Top-line results may not accurately reflect the complete results of the trials.
• The company's cash balance may not be sufficient to fund all planned activities.

Future Outlook

Relmada plans to advance NDV-01 and sepranolone through key development milestones, including FDA interactions and initiating registration-track studies in late Q4 2025 to early 2026. The company believes its cash balance is adequate to support planned operations through key milestones into H1 2026.

Management Comments

• 'We believe each program represents exceptional value-creation opportunities for our investors,' said Sergio Traversa, CEO of Relmada Therapeutics.
• Maged Shenouda, CFO of Relmada, commented that the broad drug development expertise of their team provides flexibility to be opportunistic in evaluating strategic opportunities.

Industry Context

Relmada is focusing on underserved markets with its NDV-01 and sepranolone programs. NDV-01 targets high-grade NMIBC, where approved treatment options are limited, and BCG immunotherapy has supply constraints. Sepranolone targets Tourette syndrome and other compulsivity disorders, offering a novel approach by modulating allopregnanolone.

Comparison to Industry Standards

• For NDV-01, companies like CG Oncology are developing bladder cancer therapies, with CG Onocology's cretostimogene grenadenorepvec showing promise in BCG-unresponsive NMIBC.
• Relmada's approach with NDV-01, using a sustained-release formulation of gemcitabine and docetaxel, aims to improve efficacy and reduce side effects compared to conventional intravesical instillations.
• For Sepranolone, companies like Teva Pharmaceutical and Neurocrine Biosciences have treatments for Tourette syndrome, but Relmada's approach of modulating allopregnanolone offers a novel mechanism of action.
• Relmada's cash balance of $44.8 million is relatively modest compared to larger pharmaceutical companies, but it is expected to be sufficient to fund planned operations into H1 2026.

Stakeholder Impact

• Shareholders can expect potential value creation from the advancement of NDV-01 and sepranolone.
• Patients with high-grade NMIBC and Tourette syndrome may benefit from the development of new treatment options.
• Employees may be affected by the re-evaluation of the P11 program and the company's prioritization efforts.

Next Steps

• Present topline Phase 2 data for NDV-01 at the AUA meeting in April 2025.
• Interact with the FDA to align on regulatory strategy for NDV-01 and sepranolone.
• Complete production of the next batch of material for NDV-01 and sepranolone.
• Finalize the design of the next studies for NDV-01 and sepranolone, expected to begin around year-end 2025 or first quarter 2026.

Key Dates

Keywords

Relmada Therapeutics, NDV-01, Sepranolone, Bladder Cancer, Tourette Syndrome, Financial Results, Phase 2, Clinical Trials, Biotechnology